nach oben

Erschienen in:

15.09.2021 | review

Diagnostic and therapeutic considerations in pediatric uveitis

verfasst von: Dimitrios Kalogeropoulos, MD, MSc, PhDc, Ioannis Asproudis, Maria Stefaniotou, Marilita Moschos, Robert Barry, Velota Sung, Sophia Tsabouri, Chris Kalogeropoulos

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Summary

Background

The management of uveitis in children can be extremely challenging as they constitute a unique population of patients. The aim of this review is to summarize current knowledge encompassing the clinical findings, diagnostic work-up, and therapeutic approach of uveitis in children.

Material and methods

A thorough literature search was performed of PubMed. An additional search was made in Google Scholar to complete the collected items.

Results

Uveitis is less common in children than in adults, but it may be more complicated due to its often asymptomatic nature or due to the inability of children to express complaints. Uveitis in children can be chronic, persistent, recurrent, and resistant to conventional treatment. The most common type of uveitis in pediatric patients is anterior uveitis, whereas the prevalence of intermediate, posterior, and panuveitis depends on the ethnic group and geographical distribution. Although many cases of pediatric uveitis are idiopathic, the differential diagnosis requires awareness of etiologies, as uveitis in children may be associated with various systemic inflammatory disorders, infections, or masquerade syndromes. Ocular complications of uveitis include cataracts, synechiae formation, glaucoma or hypotony, band keratopathy, macular edema, epiretinal membrane, choroidal neovascular membranes, and retinal detachment. These complications are associated with not only the nature of the disease but also with the use of topical and systemic corticosteroids, leading to irreversible structural damage and visual loss.

Conclusion

The therapeutic approach depends on the etiologic factor and the individual characteristics of each patient. Regular monitoring is crucial for early detection of any complications of uveitis or even adverse effects from treatments. Multidisciplinary management is also vital for providing more holistic care to young patients and their families ensuring a better quality of life. This study aims to review the current literature on the management of uveitis in pediatric patients.

Vorheriger Artikel The clinical importance of uveomeningeal syndromes

Nächster Artikel Early-onset sarcoidosis with R334Q mutation in the NOD2 gene

Holland GN, Stiehm ER. Special considerations in the evaluation and management of uveitis in children. Am J Ophthalmol. 2003;135(6):867–78. https://doi.org/10.1016/s0002-9394(03)00314-3.CrossRefPubMed

Kalogeropoulos D, Kalogeropoulos C, Moschos MM, Sung V. The management of uveitic glaucoma in children. Turk J Ophthalmol. 2019;49(5):283–93. https://doi.org/10.4274/tjo.galenos.2019.36589.CrossRefPubMedPubMedCentral

Kalogeropoulos D, Sung VC. Pathogenesis of uveitic glaucoma. J Curr Glaucoma Pract. 2018;12(3):125–38. https://doi.org/10.5005/jp-journals-10028-1257.CrossRefPubMedPubMedCentral

Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111(12):2299–306. https://doi.org/10.1016/j.ophtha.2004.06.014.CrossRefPubMed

Gautam Seth N, Kaur S, Yangzes S, et al. Ophthalmic complications in pediatric uveitis. Ocul Immunol Inflamm. 2020; https://doi.org/10.1080/09273948.2020.1762897.CrossRefPubMed

Keino H, Watanabe T, Taki W, et al. Clinical features of uveitis in children and adolescents at a tertiary referral centre in Tokyo. Br J Ophthalmol. 2017;101(4):406–10. https://doi.org/10.1136/bjophthalmol-2015-308194.CrossRefPubMed

Ferrara M, Eggenschwiler L, Stephenson A, et al. The challenge of pediatric uveitis: tertiary referral center experience in the United States. Ocul Immunol Inflamm. 2019;27(3):410–7. https://doi.org/10.1080/09273948.2017.1420202.CrossRefPubMed

Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol. 2003;135(5):676–80. https://doi.org/10.1016/s0002-9394(02)02148-7.CrossRefPubMed

Sung VC, Barton K. Management of inflammatory glaucomas. Curr Opin Ophthalmol. 2004;15(2):136–40. https://doi.org/10.1097/00055735-200404000-00014.CrossRefPubMed

10.

Gaggiano C, Sota J, Gentileschi S, et al. The current status of biological treatment for uveitis. Expert Rev Clin Immunol. 2020;16(8):787–811. https://doi.org/10.1080/1744666X.2020.1798230.CrossRefPubMed

11.

Päivönsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000;78(1):84–8. https://doi.org/10.1034/j.1600-0420.2000.078001084.x.CrossRefPubMed

12.

Tugal-Tutkun I. Pediatric uveitis. J Ophthalmic Vis Res. 2011;6(4):259–69.PubMedPubMedCentral

13.

Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116(8):1544–1551.e1. https://doi.org/10.1016/j.ophtha.2009.05.002.CrossRefPubMed

14.

Kump LI, Cervantes-Castañeda RA, Androudi SN, Foster CS. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology. 2005;112(7):1287–92. https://doi.org/10.1016/j.ophtha.2005.01.044.CrossRefPubMed

15.

Siiskonen M, Hirn I, Pesälä R, Hautala T, Ohtonen P, Hautala N. Prevalence, incidence and epidemiology of childhood uveitis. Acta Ophthalmol. 2020; https://doi.org/10.1111/aos.14535.CrossRefPubMed

16.

Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Rheum Dis Clin North Am. 2007;33(3):441–vi. https://doi.org/10.1016/j.rdc.2007.07.006.CrossRefPubMed

17.

Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56(2):647–57. https://doi.org/10.1002/art.22381.CrossRefPubMed

18.

Rathinam SR, Namperumalsamy P. Global variation and pattern changes in epidemiology of uveitis. Indian J Ophthalmol. 2007;55(3):173–83. https://doi.org/10.4103/0301-4738.31936.CrossRefPubMed

19.

Asproudis I, Katsanos A, Kozeis N, Tantou A, Konstas AG. Update on the treatment of uveitis in patients with juvenile idiopathic arthritis: a review. Adv Ther. 2017;34(12):2558–65. https://doi.org/10.1007/s12325-017-0635-3.CrossRefPubMed

20.

Ohm J. Bandförmige Hornhauttrübung bei einem neunjährigen Mädchen und ihre Behandlung mit subconjunctivalen Jodkaliumeinspritzungen. Klin Monatsbl Augenheilkd. 1910;48:243–6.

21.

Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS. 2008;12(6):539–45. https://doi.org/10.1016/j.jaapos.2008.03.007.CrossRefPubMed

22.

Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35(5):777–85. https://doi.org/10.1007/s00296-015-3231-3.CrossRefPubMed

23.

Davies K, Cleary G, Foster H, Hutchinson E, Baildam E, British Society of Paediatric and Adolescent Rheumatology. BSPAR standards of care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49(7):1406–8. https://doi.org/10.1093/rheumatology/kep460.CrossRefPubMed

24.

Hoeve M, Kalinina Ayuso V, Schalij-Delfos NE, Los LI, Rothova A, de Boer JH. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty. Br J Ophthalmol. 2012;96(6):852–6. https://doi.org/10.1136/bjophthalmol-2011-301023.CrossRefPubMed

25.

Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm. 2013;21(3):180–91. https://doi.org/10.3109/09273948.2013.791701.CrossRefPubMed

26.

Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):281–90. https://doi.org/10.1007/s00417-005-0087-3.CrossRefPubMed

27.

Foeldvari I. Ocular involvement in juvenile idiopathic arthritis: classification and treatment. Clin Rev Allergy Immunol. 2015;49(3):271–7. https://doi.org/10.1007/s12016-014-8436-9.CrossRefPubMed

28.

Qian Y, Acharya NR. Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2010;21(6):468–72. https://doi.org/10.1097/ICU.0b013e32833eab83.CrossRefPubMedPubMedCentral

29.

Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015;11(6):338–48. https://doi.org/10.1038/nrrheum.2015.20.CrossRefPubMed

30.

Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104(2):236–44. https://doi.org/10.1016/s0161-6420(97)30329-7.CrossRefPubMed

31.

Kanski JJ. Screening for uveitis in juvenile chronic arthritis. Br J Ophthalmol. 1989;73(3):225–8. https://doi.org/10.1136/bjo.73.3.225.CrossRefPubMedPubMedCentral

32.

Keenan JD, Tessler HH, Goldstein DA. Granulomatous inflammation in juvenile idiopathic arthritis-associated uveitis. J AAPOS. 2008;12(6):546–50. https://doi.org/10.1016/j.jaapos.2008.05.012.CrossRefPubMed

33.

Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143(5):840–6. https://doi.org/10.1016/j.ajo.2007.01.033.CrossRefPubMed

34.

Kump LI, Castañeda RA, Androudi SN, Reed GF, Foster CS. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology. 2006;113(10):1874–7. https://doi.org/10.1016/j.ophtha.2006.05.016.CrossRefPubMed

35.

Sijssens KM, Rothova A, Van De Vijver DA, Stilma JS, De Boer JH. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;144(4):574–9. https://doi.org/10.1016/j.ajo.2007.06.030.CrossRefPubMed

36.

Wells JM, Smith JR. Uveitis in juvenile idiopathic arthritis: recent therapeutic advances. Ophthalmic Res. 2015;54(3):124–7. https://doi.org/10.1159/000438758.CrossRefPubMed

37.

Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–16. https://doi.org/10.1016/j.ajo.2005.03.057.CrossRefPubMed

38.

Tang WM, Pulido JS, Eckels DD, Han DP, Mieler WF, Pierce K. The association of HLA-DR15 and intermediate uveitis. Am J Ophthalmol. 1997;123(1):70–5. https://doi.org/10.1016/s0002-9394(14)70994-8.CrossRefPubMed

39.

Arellanes-García L, Navarro-López P, Concha-Del Río LE, Unzueta-Medina JA. Idiopathic intermediate uveitis in childhood. Int Ophthalmol Clin. 2008;48(3):61–74. https://doi.org/10.1097/IIO.0b013e31817d84af.CrossRefPubMed

40.

Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clin Exp Ophthalmol. 2001;29(2):81–4.CrossRefPubMed

41.

Romero R, Peralta J, Sendagorta E, Abelairas J. Pars planitis in children: epidemiologic, clinical, and therapeutic characteristics. J Pediatr Ophthalmol Strabismus. 2007;44(5):288–93. https://doi.org/10.3928/01913913-20070901-03.CrossRefPubMed

42.

de Boer J, Berendschot TT, van der Does P, Rothova A. Long-term follow-up of intermediate uveitis in children. Am J Ophthalmol. 2006;141(4):616–21. https://doi.org/10.1016/j.ajo.2005.09.035.CrossRefPubMed

43.

Kalinina Ayuso V, ten Cate HA, van den Does P, Rothova A, de Boer JH. Young age as a risk factor for complicated course and visual outcome in intermediate uveitis in children. Br J Ophthalmol. 2011;95(5):646–51. https://doi.org/10.1136/bjo.2010.184267.CrossRefPubMed

44.

Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS. 2008;12(6):611–3. https://doi.org/10.1016/j.jaapos.2008.08.007.CrossRefPubMed

45.

Tugal-Tutkun I. Behçet’s uveitis. Middle East Afr J Ophthalmol. 2009;16(4):219–24. https://doi.org/10.4103/0974-9233.58425.CrossRefPubMedPubMedCentral

46.

Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet’s disease, the silk road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54(3):213–20. https://doi.org/10.1034/j.1399-0039.1999.540301.x.CrossRefPubMed

47.

Keino H, Okada AA. Behçet’s disease: global epidemiology of an old silk road disease. Br J Ophthalmol. 2007;91(12):1573–4. https://doi.org/10.1136/bjo.2007.124875.CrossRefPubMedPubMedCentral

48.

Azizlerli G, Köse AA, Sarica R, et al. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803–6. https://doi.org/10.1046/j.1365-4362.2003.01893.x.CrossRefPubMed

49.

Mohammad A, Mandl T, Sturfelt G, Segelmark M. Incidence, prevalence and clinical characteristics of Behcet’s disease in southern Sweden. Rheumatology (Oxford). 2013;52(2):304–10. https://doi.org/10.1093/rheumatology/kes249.CrossRefPubMed

50.

Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S. Low prevalence of juvenile-onset Behcet’s disease with uveitis in East/South Asian people. Br J Ophthalmol. 2009;93(11):1428–30. https://doi.org/10.1136/bjo.2008.154476.CrossRefPubMed

51.

Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol. 1982;100(9):1455–8. https://doi.org/10.1001/archopht.1982.01030040433013.CrossRefPubMed

52.

Gül A. Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4(1):81–3. https://doi.org/10.2174/1568010053622894.CrossRefPubMed

53.

Direskeneli H. Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford). 2006;45(12):1461–5. https://doi.org/10.1093/rheumatology/kel329.CrossRefPubMed

54.

Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behçet disease:a descriptive study of 36 cases. Am J Ophthalmol. 2003;136(6):1114–9. https://doi.org/10.1016/s0002-9394(03)00791-8.CrossRefPubMed

55.

Borlu M, Ukşal U, Ferahbaş A, Evereklioglu C. Clinical features of Behçet’s disease in children. Int J Dermatol. 2006;45(6):713–6. https://doi.org/10.1111/j.1365-4632.2006.02754.x.CrossRefPubMed

56.

Sungur GK, Hazirolan D, Yalvac I, et al. Clinical and demographic evaluation of Behçet disease among different paediatric age groups. Br J Ophthalmol. 2009;93(1):83–7. https://doi.org/10.1136/bjo.2007.137141.CrossRefPubMed

57.

Koné-Paut I, Darce-Bello M, Shahram F, et al. Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011;50(1):184–8. https://doi.org/10.1093/rheumatology/keq324.CrossRefPubMed

58.

Saricaoglu H, Karadogan SK, Bayazit N, Yucel A, Dilek K, Tunali S. Clinical features of late-onset Behçet’s disease: report of nine cases. Int J Dermatol. 2006;45(11):1284–7. https://doi.org/10.1111/j.1365-4632.2006.02921.x.CrossRefPubMed

59.

Kitaichi N, Ohno S. Behçet disease in children. Int Ophthalmol Clin. 2008;48(3):87–91. https://doi.org/10.1097/IIO.0b013e31817d8393.CrossRefPubMed

60.

Kesen MR, Goldstein DA, Tessler HH. Uveitis associated with pediatric Behçet disease in the American Midwest. Am J Ophthalmol. 2008;146(6):819–827.e2. https://doi.org/10.1016/j.ajo.2008.05.043.CrossRefPubMed

61.

Citirik M, Berker N, Songur MS, Soykan E, Zilelioglu O. Ocular findings in childhood-onset Behçet disease. J AAPOS. 2009;13(4):391–5. https://doi.org/10.1016/j.jaapos.2009.04.016.CrossRefPubMed

62.

Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50(4):297–350. https://doi.org/10.1016/j.survophthal.2005.04.009.CrossRefPubMed

63.

Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behcet’s disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579–82. https://doi.org/10.1136/bjo.2007.123554.CrossRefPubMedPubMedCentral

64.

Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362–8.PubMed

65.

Kawaguchi T, Hanada A, Horie S, Sugamoto Y, Sugita S, Mochizuki M. Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis patients. Jpn J Ophthalmol. 2007;51(2):121–6. https://doi.org/10.1007/s10384-006-0413-2.CrossRefPubMed

66.

Manouvrier-Hanu S, Puech B, Piette F, et al. Blau syndrome of granulomatous arthritis, iritis, and skin rash: a new family and review of the literature. Am J Med Genet. 1998;76(3):217–21.CrossRefPubMed

67.

Wu S, Zhong L, Sun Z, Zhu T, Song H, Sui R. Ocular features in Chinese patients with Blau syndrome. Ocul Immunol Inflamm. 2020;28(1):79–85. https://doi.org/10.1080/09273948.2019.1569239.CrossRefPubMed

68.

Punzi L, Furlan A, Podswiadek M, et al. Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmun Rev. 2009;8(3):228–32. https://doi.org/10.1016/j.autrev.2008.07.034.CrossRefPubMed

69.

Kahkouee S, Samadi K, Alai A, Abedini A, Rezaiian L. Serum ACE level in sarcoidosis patients with typical and atypical HRCT manifestation. Pol J Radiol. 2016;81:458–61. https://doi.org/10.12659/PJR.897708.CrossRefPubMedPubMedCentral

70.

Shetty AK, Gedalia A. Childhood sarcoidosis: a rare but fascinating disorder. Pediatr Rheumatol Online J. 2008;6:16. https://doi.org/10.1186/1546-0096-6-16.CrossRefPubMedPubMedCentral

71.

Herbort CP, Rao NA, Mochizuki M, members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first international workshop on ocular sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17(3):160–9. https://doi.org/10.1080/09273940902818861.CrossRefPubMed

72.

Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46(2):111–22. https://doi.org/10.1097/00004397-200604620-00011.CrossRefPubMed

73.

Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–52. https://doi.org/10.1016/s0002-9394(01)00925-4.CrossRefPubMed

74.

Wakabayashi T, Morimura Y, Miyamoto Y, Okada AA. Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm. 2003;11(4):277–86. https://doi.org/10.1076/ocii.11.4.277.18260.CrossRefPubMed

75.

Tabbara KF, Chavis PS, Freeman WR. Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand. 1998;76(6):723–6. https://doi.org/10.1034/j.1600-0420.1998.760619.x.CrossRefPubMed

76.

Rathinam SR, Vijayalakshmi P, Namperumalsamy P, Nozik RA, Cunningham ET Jr.. Vogt-Koyanagi-Harada syndrome in children. Ocul Immunol Inflamm. 1998;6(3):155–61. https://doi.org/10.1076/ocii.6.3.155.4041.CrossRefPubMed

77.

Abu El-Asrar AM, Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D. Vogt-Koyanagi-Harada disease in children. Eye (Lond). 2008;22(9):1124–31. https://doi.org/10.1038/sj.eye.6702859.CrossRefPubMed

78.

Mackensen F, Smith JR, Rosenbaum JT. Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology. 2007;114(5):995–9. https://doi.org/10.1016/j.ophtha.2007.01.002.CrossRefPubMed

79.

Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol. 2001;46(3):195–208. https://doi.org/10.1016/s0039-6257(01)00261-2.CrossRefPubMed

80.

Levinson RD. Tubulointerstitial nephritis and uveitis syndrome. Int Ophthalmol Clin. 2008;48(3):51–9. https://doi.org/10.1097/IIO.0b013e31817d8455.CrossRefPubMed

81.

Kalogeropoulos D, Kalogeropoulos C, Sakkas H, et al. Pathophysiological aspects of ocular toxoplasmosis: host-parasite interactions. Ocul Immunol Inflamm. 2021; https://doi.org/10.1080/09273948.2021.1922706.CrossRefPubMed

82.

Giles CL. Uveitis in childhood—part III. Posterior. Ann Ophthalmol. 1989;21(1):23–8.PubMed

83.

Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol. 2003;136(6):973–88. https://doi.org/10.1016/j.ajo.2003.09.040.CrossRefPubMed

84.

SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thiébaut R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data. Lancet. 2007;369(9556):115–22. https://doi.org/10.1016/S0140-6736(07)60072-5.CrossRef

85.

Vasconcelos-Santos DV, Machado Azevedo DO, Campos WR, et al. Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology. 2009;116(11):2199–2205.e1. https://doi.org/10.1016/j.ophtha.2009.04.042.CrossRefPubMed

86.

Meenken C, Assies J, van Nieuwenhuizen O, et al. Long term ocular and neurological involvement in severe congenital toxoplasmosis. Br J Ophthalmol. 1995;79(6):581–4. https://doi.org/10.1136/bjo.79.6.581.CrossRefPubMedPubMedCentral

87.

de Jong PT. Ocular toxoplasmosis; common and rare symptoms and signs. Int Ophthalmol. 1989;13(6):391–7. https://doi.org/10.1007/BF02306487.CrossRefPubMed

88.

Loewer-Sieger DH, Rothova A, Koppe JG, et al. Congenital toxoplasmosis: a prospective study based on 1821 pregnant women. In: Saari KM, editor. Uveitis update. Amsterdam: Elsevier; 1984. pp. 203–7.

89.

Roizen N, Kasza K, Karrison T, et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006;118(2):e379–e90. https://doi.org/10.1542/peds.2005-1530.CrossRefPubMed

90.

Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109(5):869–78. https://doi.org/10.1016/s0161-6420(02)00990-9.CrossRefPubMed

91.

Tan HK, Schmidt D, Stanford M, et al. Risk of visual impairment in children with congenital toxoplasmic retinochoroiditis. Am J Ophthalmol. 2007;144(5):648–53. https://doi.org/10.1016/j.ajo.2007.07.013.CrossRefPubMed

92.

Montoya JG. Laboratory diagnosis of toxoplasma gondii infection and toxoplasmosis. J Infect Dis. 2002;185(1):S73–S82. https://doi.org/10.1086/338827.CrossRefPubMed

93.

Liu Q, Wang ZD, Huang SY, Zhu XQ. Diagnosis of toxoplasmosis and typing of toxoplasma gondii. Parasit Vectors. 2015;8:292. https://doi.org/10.1186/s13071-015-0902-6.CrossRefPubMedPubMedCentral

94.

Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M. Duration of the IgM response in women acquiring toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect. 2004;132(3):541–8. https://doi.org/10.1017/s0950268803001948.CrossRefPubMedPubMedCentral

95.

Olariu TR, Press C, Talucod J, Olson K, Montoya JG. Congenital toxoplasmosis in the United States: clinical and serologic findings in infants born to mothers treated during pregnancy. Parasite. 2019;26:13. https://doi.org/10.1051/parasite/2019013.CrossRefPubMedPubMedCentral

96.

Findal G, Stray-Pedersen B, Holter EK, Berge T, Jenum PA. Persistent low toxoplasma IgG avidity is common in pregnancy: experience from antenatal testing in Norway. PLoS ONE. 2015;10(12):e145519. https://doi.org/10.1371/journal.pone.0145519.CrossRefPubMedPubMedCentral

97.

Wilder HC. Toxoplasma chorioretinitis in adults. AMA Arch Ophthalmol. 1952;48(2):127–36. https://doi.org/10.1001/archopht.1952.00920010132001.CrossRefPubMedADS

98.

Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):102–14. https://doi.org/10.1016/s0002-9394(02)01526-x.CrossRefPubMed

99.

Kalogeropoulos D, Anastasopoulos D, Gartzonika C, et al. Acute retinal necrosis in a patient with HSV‑1 encephalitis. BAOJ Ophthalmol. 2017;2:9.

100.

Vandercam T, Hintzen RQ, de Boer JH, Van der Lelij A. Herpetic encephalitis is a risk factor for acute retinal necrosis. Neurology. 2008;71(16):1268–74. https://doi.org/10.1212/01.wnl.0000327615.99124.99.CrossRefPubMed

101.

Wong RW, Cunningham ET. Diagnosing and managing acute retinal necrosis. A variety of treatment options exist for this rare but troubling condition. Retin Physician. 2013;10:201338–45.

102.

Singh M, Dhir L, Kon C, Rassam S. Tractional retinal break and rhegmatogenous retinal detachment consequent to branch retinal vein occlusion. Eye (Lond). 2006;20(11):1326–7. https://doi.org/10.1038/sj.eye.6702195.CrossRefPubMed

103.

Kianersi F, Masjedi A, Ghanbari H. Acute retinal necrosis after herpetic encephalitis. Case Rep Ophthalmol. 2010;1(2):85–9. https://doi.org/10.1159/000321708.CrossRefPubMedPubMedCentral

104.

McGrath L, Woods M, Lee L, Conrad D. Acute retinal necrosis (ARN) in the context of neonatal HSV‑2 exposure and subconjunctival dexamethasone: case report and literature review. Digit J Ophthalmol. 2013;19(2):28–32. https://doi.org/10.5693/djo.02.2013.02.004.CrossRefPubMedPubMedCentral

105.

Holland GN. Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive committee of the American Uveitis society. Am J Ophthalmol. 1994;117(5):663–7. https://doi.org/10.1016/s0002-9394(14)70075-3.CrossRefPubMed

106.

Gartry DS, Spalton DJ, Tilzey A, Hykin PG. Acute retinal necrosis syndrome. Br J Ophthalmol. 1991;75(5):292–7. https://doi.org/10.1136/bjo.75.5.292.CrossRefPubMedPubMedCentral

107.

Lau CH, Missotten T, Salzmann J, Lightman SL. Acute retinal necrosis features, management, and outcomes. Ophthalmology. 2007;114(4):756–62. https://doi.org/10.1016/j.ophtha.2006.08.037.CrossRefPubMed

108.

Muthiah MN, Michaelides M, Child CS, Mitchell SM. Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK. Br J Ophthalmol. 2007;91(11):1452–5. https://doi.org/10.1136/bjo.2007.114884.CrossRefPubMedPubMedCentral

109.

Takase H, Goto H, Namba K, et al. Clinical characteristics, management, and factors associated with poor visual prognosis of acute retinal necrosis. Ocul Immunol Inflamm. 2020; https://doi.org/10.1080/09273948.2020.1789179.CrossRefPubMed

110.

WHO. Tuberculosis. 2020. https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed 23 Jan 2021.

111.

Kalogeropoulos D, Kitsos G, Konstantinidis A, et al. Tuberculous posterior sclero-uveitis with features of Vogt-Koyanagi-Harada uveitis: an unusual case. Am J Case Rep. 2017;18:367–74. https://doi.org/10.12659/ajcr.903304.CrossRefPubMedPubMedCentral

112.

Helm CJ, Holland GN. Ocular tuberculosis. Surv Ophthalmol. 1993;38(3):229–56. https://doi.org/10.1016/0039-6257(93)90076-j.CrossRefPubMed

113.

Al-Shakarchi F. Mode of presentations and management of presumed tuberculous uveitis at a referral center. Iraqi. Postgrad Med J. 2015;14(1):91–5.

114.

McMoli TE, Mordi VP, Grange A, Abiose A. Tuberculous panophthalmitis. J Pediatr Ophthalmol Strabismus. 1978;15(6):383–5.CrossRefPubMed

115.

Schlossberg D, Maher D, Raviglione MC. The global epidemic of tuberculosis: a World Health Organization perspective. In: Schlossberg D, editor. Tuberculosis and nontuberculous mycobacterial infections. 4th ed. Philadelphia: WB Saunders Company; 1999. pp. 104–15.

116.

Gupta A, Bansal R, Gupta V, Sharma A, Bambery P. Ocular signs predictive of tubercular uveitis. Am J Ophthalmol. 2010;149(4):562–70. https://doi.org/10.1016/j.ajo.2009.11.020.CrossRefPubMed

117.

Sheu SJ, Shyu JS, Chen LM, Chen YY, Chirn SC, Wang JS. Ocular manifestations of tuberculosis. Ophthalmology. 2001;108(9):1580–5. https://doi.org/10.1016/s0161-6420(01)00693-5.CrossRefPubMed

118.

Samson MC, Foster CS. Tuberculosis. In: Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. Philadelphia: Saunders; 2002. pp. 264–72.

119.

Varma D, Anand S, Reddy AR, et al. Tuberculosis: an under-diagnosed aetiological agent in uveitis with an effective treatment. Eye (Lond). 2006;20(9):1068–73. https://doi.org/10.1038/sj.eye.6702093.CrossRefPubMed

120.

Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine. 1984;63(1):25–55.CrossRefPubMed

121.

Shirodkar A, Albini T. Tuberculosis: intraocular involvement. Rev Ophtalmol. 2010;17(3):P59.

122.

Alvarez GG, Roth VR, Hodge W. Ocular tuberculosis: diagnostic and treatment challenges. Int J Infect Dis. 2009;13(4):432–5. https://doi.org/10.1016/j.ijid.2008.09.018.CrossRefPubMed

123.

Chan NS, Choi J, Cheung CMG. Pediatric uveitis. Asia Pac J Ophthalmol (Phila). 2018;7(3):192–9. https://doi.org/10.22608/APO.2018116.CrossRefPubMed

124.

Habot-Wilner Z, Sallam A, Roufas A, et al. Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol. 2010;88(8):e299–e304. https://doi.org/10.1111/j.1755-3768.2010.02025.x.CrossRefPubMed

125.

Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151(2):217–22. https://doi.org/10.1016/j.ajo.2010.08.021.CrossRefPubMed

126.

127.

Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144(6):844–9. https://doi.org/10.1016/j.ajo.2007.08.018.CrossRefPubMedPubMedCentral

128.

Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572–5. https://doi.org/10.1016/j.jpeds.2006.04.058.CrossRefPubMed

129.

Mansour AM. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):274–6. https://doi.org/10.1136/bjo.2006.108050.CrossRefPubMedPubMedCentral

130.

Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23. https://doi.org/10.1002/art.20904.CrossRefPubMed

131.

Kaipiainen-Seppänen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis. 2003;62(1):88–9. https://doi.org/10.1136/ard.62.1.88.CrossRefPubMed

132.

Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003;87(7):925. https://doi.org/10.1136/bjo.87.7.925.CrossRefPubMedPubMedCentral

133.

Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev. 2010;9(10):674–83. https://doi.org/10.1016/j.autrev.2010.05.017.CrossRefPubMed

134.

Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009;148(5):696–703.e1. https://doi.org/10.1016/j.ajo.2009.06.003.CrossRefPubMedPubMedCentral

135.

Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(6):821–5. https://doi.org/10.1002/acr.20115.CrossRefPubMed

136.

Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50:1390–4.CrossRefPubMed

137.

Quiñones K, Cervantes-Castañeda RA, Hynes AY, Daoud YJ, Foster CS. Outcomes of cataract surgery in children with chronic uveitis. J Cataract Refract Surg. 2009;35(4):725–31. https://doi.org/10.1016/j.jcrs.2008.12.014.CrossRefPubMed

138.

Flynn HW Jr, Davis JL, Culbertson WW. Pars plana lensectomy and vitrectomy for complicated cataracts in juvenile rheumatoid arthritis. Ophthalmology. 1988;95(8):1114–9. https://doi.org/10.1016/s0161-6420(88)33051-4.CrossRefPubMed

139.

Yangzes S, Seth NG, Singh R, et al. Long-term outcomes of cataract surgery in children with uveitis. Indian J Ophthalmol. 2019;67(4):490–5. https://doi.org/10.4103/ijo.IJO_846_18.CrossRefPubMedPubMedCentral

140.

Angeles-Han ST. Quality-of-life metrics in pediatric uveitis. Int Ophthalmol Clin. 2015;55(2):93–101. https://doi.org/10.1097/IIO.0000000000000067.CrossRefPubMedPubMedCentral

141.

The WHOQOL Group. The development of the World Health Organization Quality of Life assessment instrument (the WHOQOL). Berlin: Springer; 1994.CrossRef

142.

Maca SM, Amirian A, Prause C, Gruber K, Mejdoubi L, Barisani-Asenbauer T. Understanding the impact of uveitis on health-related quality of life in adolescents. Acta Ophthalmol. 2013;91(3):e219–e24. https://doi.org/10.1111/aos.12016.CrossRefPubMed

143.

Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children ages 8–18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken). 2011;63(9):1254–61. https://doi.org/10.1002/acr.20524.CrossRefPubMed

Titel: Diagnostic and therapeutic considerations in pediatric uveitis
verfasst von: Dimitrios Kalogeropoulos, MD, MSc, PhDc
Ioannis Asproudis
Maria Stefaniotou
Marilita Moschos
Robert Barry
Velota Sung
Sophia Tsabouri
Chris Kalogeropoulos
Publikationsdatum: 15.09.2021
Verlag: Springer Vienna
Erschienen in: Spektrum der Augenheilkunde / Ausgabe 1/2024
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI: https://doi.org/10.1007/s00717-021-00503-8

Springer Medizin Österreich

Summary

Background

Material and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

A comparative study on the use of fibrin glue versus sutures in pterygium surgery with conjunctivolimbal autograft and its impact on higher-order aberrations

Retinoblastom Report Österreich 2021

The clinical importance of uveomeningeal syndromes

Early-onset sarcoidosis with R334Q mutation in the NOD2 gene

DFP: Antikoagulation und Thrombozytenfunktionshemmung